
|Videos|January 3, 2018
Current and Emerging Immunotherapeutic Strategies in Melanoma
Author(s)Patrick Ott, MD, PhD
Patrick Ott, MD, PhD, clinical director, Melanoma Center, Center for Immuno-Oncology, physician, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses current and emerging immunotherapeutic strategies in melanoma.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Sacituzumab Govitecan Misses PFS in First-Line HR+/HER2– Metastatic Breast Cancer
2
First-in-Human Data Support Izalontamab in Advanced Epithelial Tumors
3
FDA Approves Subcutaneous Daratumumab for Smoldering Multiple Myeloma
4
Lurbinectedin and Tarlatamab in ES-SCLC
5








































